Evidence map›Paper›PMID 29432954›Full record

ReviewSeminars in cell & developmental biology2019

Mechanistic insights and therapeutic opportunities of antimicrobial chemokines.

Matthew A Crawford, Katie R Margulieux, Arpita Singh, Robert K Nakamoto, Molly A Hughes

Open access · hybridAbstract readReview
In one paragraph

Review in Seminars in cell & developmental biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Matthew A CrawfordDivision of Infectious Diseases & International Health, Department of Medicine, University of Virginia, Charlottesville, VA, 22908, USA.
Katie R MargulieuxDepartment of Enteric Diseases, Armed Forces Research Institute of Medical Sciences, Bangkok 10400, Thailand.
Arpita SinghDivision of Infectious Diseases & International Health, Department of Medicine, University of Virginia, Charlottesville, VA, 22908, USA.
Robert K NakamotoDepartment of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA, 22908, USA.
Molly A HughesDivision of Infectious Diseases & International Health, Department of Medicine, University of Virginia, Charlottesville, VA, 22908, USA. Electronic address: mah3x@virginia.edu.
University of Virginia · USArmed Forces Research Institute of Medical Science · TH

Funding

Bacillus anthracis Targets Involved in Chemokine-Mediated Antimicrobial ActivityR01AI099097 · NIAID · UNIVERSITY OF VIRGINIA · PI HUGHES, MOLLY A · 2013 to 2016
$1.6M
Molecular study of DksA as a smart switch central to Salmonella pathogenesisF32AI108249 · NIAID · UNIVERSITY OF VIRGINIA · PI CRAWFORD, MATTHEW ANTHONY · 2014 to 2016
$155k
NIAID NIH HHS F32 AI108249NIAID NIH HHS R01 AI099097
6 · The paper itself

Abstract

Chemokines are a family of small proteins best known for their ability to orchestrate immune cell trafficking and recruitment to sites of infection. Their role in promoting host defense is multiplied by a number of additional receptor-dependent biological activities, and most, but not all, chemokines have been found to mediate direct antimicrobial effects against a broad range of microorganisms. The molecular mechanism(s) by which antimicrobial chemokines kill bacteria remains unknown; however, recent observations have expanded our fundamental understanding of chemokine-mediated bactericidal activity to reveal increasingly diverse and complex actions. In the current review, we present and consider mechanistic insights of chemokine-mediated antimicrobial activity against bacteria. We also discuss how contemporary advances are reshaping traditional paradigms and opening up new and innovative avenues of research with translational implications. Towards this end, we highlight a developing framework for leveraging chemokine-mediated bactericidal and immunomodulatory effects to advance pioneering therapeutic approaches for treating bacterial infections, including those caused by multidrug-resistant pathogens.

Indexed as

AnimalsAnti-Infective AgentsBacteriaBacterial InfectionsCell MembraneCell WallChemokinesDrug Resistance, BacterialHumansPeptidoglycanProtein Structure, SecondaryStructure-Activity RelationshipAnti-Infective AgentsChemokinesPeptidoglycanAntimicrobialBacteriaChemokineMechanismPeptideTherapeutic

Identifiers

PMID29432954
PMCPMC6613794
OpenAlexW2793452597

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.